These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 19773328)

  • 1. Serum tumour markers: how to order and interpret them.
    Sturgeon CM; Lai LC; Duffy MJ
    BMJ; 2009 Sep; 339():b3527. PubMed ID: 19773328
    [No Abstract]   [Full Text] [Related]  

  • 2. Serum tumour markers in clinical practice. Some general aspects.
    Kvinnsland S
    Scand J Clin Lab Invest Suppl; 1991; 206():6-11. PubMed ID: 1947761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Application of tumour markers in clinical practice].
    Keuren JF; Thomas CM; Bonfrèr JM; Sweep CG; Boonstra JG
    Ned Tijdschr Geneeskd; 2009; 153():A617. PubMed ID: 19857306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating biomarkers from tumour bulk to tumour machinery: promises and pitfalls.
    Gion M; Daidone MG
    Eur J Cancer; 2004 Nov; 40(17):2613-22. PubMed ID: 15541962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Criteria for using tumor markers. 2: Indications and interpretation].
    Fateh-Moghadam VA; Stieber P
    Fortschr Med; 1996 Mar; 114(7):38-40. PubMed ID: 8900968
    [No Abstract]   [Full Text] [Related]  

  • 6. Continuous inappropriate use of serum tumour markers.
    Tran HA
    Intern Med J; 2005 Oct; 35(10):640-1; author reply 641. PubMed ID: 16207270
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of tumour markers in cancer diagnosis and treatment.
    Higgins C
    Nurs Times; 1996 Apr 17-23; 92(16):36-7. PubMed ID: 8710591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer proteomics: Serum diagnostics for tumor marker discovery.
    Rai AJ; Chan DW
    Ann N Y Acad Sci; 2004 Jun; 1022():286-94. PubMed ID: 15251974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tumor markers--how they should be applied].
    Stieber P; Heinemann V; Schalhorn A
    MMW Fortschr Med; 2005 May; 147(20):35, 37-9. PubMed ID: 15957858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Towards evidence-based use of serum tumour marker requests: an audit of use in a tertiary hospital.
    Colls BM
    Intern Med J; 2005 Oct; 35(10):640. PubMed ID: 16207271
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.
    Belpomme D; Irigaray P
    J Natl Cancer Inst; 2010 Apr; 102(7):506-7. PubMed ID: 20190186
    [No Abstract]   [Full Text] [Related]  

  • 12. [Good clinical use of serum tumor markers].
    Boussen H; el May M; Jerbi G; Rahal K; Benna F; Mtimet S; Ben Ayed F
    Tunis Med; 1998 Feb; 76(2):1020-6. PubMed ID: 9844536
    [No Abstract]   [Full Text] [Related]  

  • 13. PSA screening: a view from the front lines. North York General-Branson Practice-Based Small Group.
    Greiver M; Rosen N
    CMAJ; 2000 Mar; 162(6):789-90. PubMed ID: 10750465
    [No Abstract]   [Full Text] [Related]  

  • 14. Tumour markers: their use and misuse by clinicians.
    McGinley PJ; Kilpatrick ES
    Ann Clin Biochem; 2003 Nov; 40(Pt 6):643-7. PubMed ID: 14629802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How the measurements of a few serum markers can be combined to enhance their clinical values in the management of cancer.
    Cordero OJ; De Chiara L; Lemos-González Y; Páez de la Cadena M; Rodríguez-Berrocal FJ
    Anticancer Res; 2008; 28(4C):2333-41. PubMed ID: 18751415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
    Barry MJ; Mulley AJ
    J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
    [No Abstract]   [Full Text] [Related]  

  • 17. Continued undertreatment of older men with localized prostate cancer.
    Carter HB
    Urology; 2004 Jul; 64(1):189-90; author reply 190. PubMed ID: 15245976
    [No Abstract]   [Full Text] [Related]  

  • 18. Tumour markers in prostate cancer: EGTM recommendations. European Group on Tumour Markers.
    Anticancer Res; 1999; 19(4A):2799-801. PubMed ID: 10470244
    [No Abstract]   [Full Text] [Related]  

  • 19. [A comparative evaluation of tumor markers (TPA and CEA) in various malignant neoplasms at an advanced stage].
    Meregalli M; Antoniazzi V; Torchio G; Colombo E; Bocchi M; Sonzini E; Lino S
    Minerva Med; 1989 Apr; 80(4):345-7. PubMed ID: 2725935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges to cancer control by screening.
    Pollak MN; Foulkes WD
    Nat Rev Cancer; 2003 Apr; 3(4):297-303. PubMed ID: 12671668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.